文献速递流行病学与生物统计真实世界研究与卫生经济

一种解读生存分析数据的新方法:描述并在三项心血管预防大型临床试验中测试

A novel method for interpreting survival analysis data: description and test on three major clinical trials on cardiovascular prevention.
PubMed 文献 · Trials · 2020-06-26

该研究提出一种基于Kaplan-Meier曲线的新方法,通过计算无事件时间增益(Time-Gain)、获得1个无事件年所需治疗月数(MoT/y+)及所需治疗患者数(NNT/y+)来解读心血管预防试验。在PROVE-IT、LIFE和HOPE三项阳性试验中,这些曲线可被二阶多项式或幂函数精确拟合,揭示不同治疗策略在效应与成本上的异质性。

要点

  • 新方法用无事件时间增益曲线描述治疗效应随时间的变化。
  • MoT/y+与NNT/y+曲线可量化获得1个无事件年的治疗暴露与患者数。
  • 三项心血管预防试验的曲线分别可由二阶多项式或幂函数精确拟合。

核心结论

  • 基于Kaplan-Meier曲线的新方法可生成关于治疗策略实际后果的新信息,以时间依赖函数形式提供临床获益。
  • 该方法有助于客观比较不同干预措施并提高预测生存的可靠性。

研究设计与样本

  • 方法学研究,从PROVE-IT、LIFE和HOPE三项阳性心血管预防试验的PDF图像中捕获原始Kaplan-Meier曲线并数字化。
  • 计算安慰剂与活性治疗曲线之差作为时间的函数,得到Time-Gain曲线。
  • 计算治疗暴露月数(MoT)与对应时间依赖的无事件年增益(月/12)之比,得到MoT/y+药经济学指数曲线。
  • 以各时间点实际治疗患者数替代MoT,得到获得1个无事件年所需治疗患者数(NNT/y+)曲线。

主要发现

  • Time-Gain曲线描绘治疗相关效应随时间的动力学,具有平滑且可被二阶多项式(a*time2 + b*time)精确拟合的特性。
  • MoT/y+和NNT/y+曲线可被幂函数(a*timeb)精确拟合。
  • 这些曲线和指数可充分体现三项试验中不同治疗策略在效应与成本上的定量与定性异质性。

临床怎么用

  • 对报告阳性结果的干预试验,可采用该方法从Kaplan-Meier曲线提取时间依赖的临床与经济有意义结果。
  • 利用Time-Gain、MoT/y+和NNT/y+曲线可辅助比较不同治疗策略并预测生存获益。

局限性

  • 方法基于从PDF图像捕获并数字化的Kaplan-Meier曲线,可能受图像数字化精度影响。
  • 仅在三项心血管预防试验中测试,外推至其他疾病领域需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Major results of randomized clinical trials on cardiovascular prevention are currently provided in terms of relative or absolute risk reductions, including also the number needed to treat (NNT), incorrectly implying that a treatment might prevent the occurrence of the outcome/s under investigation. Provided that these results are based on survival analysis, the primary measure of which is time-to-the outcome and not the outcome itself, we sought an alternative method to describe, analyse and interpret clinical trial results consistent with this assumption, so as to better define qualitative and quantitative heterogeneity of various therapeutic strategies in terms of their effects and costs. METHODS: The original Kaplan-Meier graphs of three major positive cardiovascular prevention trials (PROVE-IT, LIFE and HOPE) were captured from the PDF images of the article and then digitalized. We calculated the difference between the placebo and active treatment curves and plotted it as a function of time to describe the event-free time gain (Time-Gain) produced by the active treatment. By calculating the exposure to the active treatment in terms of months (MoT) as a function of time and dividing it for the corresponding time-dependent number of event-free years gained (i.e. months/12), we described the kinetics of the pharmaco-economic index MoT/y+. The same procedure was repeated replacing MoT with the actual number of patients being treated at each time point as a function of time to obtain the NNT to gain 1 event-free year (NNT/y+) curve. RESULTS: The Time-Gain curves depict the kinetics of the treatment-related effect over time and possess the peculiar feature of being smooth and accurately fitted by second-order polynomial functions (a*time2 + b*time); similarly, also the MoT/y+ and NNT/y+ curves can be accurately fitted by power functions (a*timeb). These curves and indices allow to fully appreciate the quantitative and qualitative heterogeneity, both in terms of effects and costs, of the different therapeutic strategies adopted in the three trials. CONCLUSIONS: With our novel method, by exploiting original Kaplan-Meier curves from three major clinical trials on cardiovascular prevention, we generate new information on the actual consequences of choosing a therapeutic strategy vs another, thus ultimately providing the clinical gain in terms of time-dependent functions. Accurately assessing clinically and economic meaningful results from any intervention trial reporting positive results through this approach, facilitates objective comparisons and increases reliability in predicting survival among the various therapeutic options provided. TRIAL REGISTRATION: PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22), Clinical trial registration number: NCT00382460, date of registration: September 29, 2006, study start date: November 2000). LIFE (Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study, Clinical trial registration number: NCT00338260, date of registration: June 20, 2006, study start date: June 1995). HOPE (Heart Outcomes Prevention Evaluation; we could not find Clinical trial registration number and date of registration).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Mengozzi A, Tricò D, Natali A, et al. A novel method for interpreting survival analysis data: description and test on three major clinical trials on cardiovascular prevention. Trials. 2020. PMID: 32586346. doi:10.1186/s13063-020-04511-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。